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Background: Prognostic markers in curable STS may have the potential to guide therapy after surgical resection.
The purpose of this study was to clarify the prognostic impact of the presence of cells and growth factors
belonging to the innate immune system in soft tissue sarcomas (STS). The significance of macrophages (CD68), their
growth factor macrophage colony-stimulating factor (M-CSF), its receptor colony-stimulating factor-1 receptor (CSF-
1R), natural killer cells (CD57) and the general immunomodulating molecule (TGF-beta) are all controversial in STS.
Herein, these markers are evaluated and compared to the cell proliferation marker Ki67.
Methods: Tissue microarrays from 249 patients with non-gastrointestinal (non-GIST) STS were constructed from
duplicate cores of viable and representative neoplastic tumor areas and duplicate cores of peritumoral capsule.
Immunohistochemistry was used to evaluate the expression of CD68, M-CSF, CSF-1R, CD57, TGF-beta and Ki67 in
tumor and peritumoral capsule.
Results: In univariate analyses increased expression of M-CSF (P = 0.034), Ki67 (P< 0.001) and TGF-beta (P = 0.003) in
tumor correlated with shorter disease-specific survival (DSS). Increased expression of CD68 in tumor correlated
significantly with malignancy grade (P = 0.016), but not DSS (P = 0.270). Increased expression of Ki67 in peritumoral
capsule tended to correlate with a shorter DSS (P = 0.057). In multivariate analyses, co-expression of M-CSF and TGF-
beta (P = 0.022) in tumor and high expression of Ki67 (P = 0.019) in peritumoral capsule were independent negative
prognostic factors for DSS.
Conclusions: Increased co-expression of M-CSF and TGF-beta in tumor in patients with STS, and increased
expression of Ki67 in peritumoral capsule were independent negative prognostic factors for DSS.
Keywords: Soft tissue sarcomas, STS, Malignancy grade, DSS, Macrophages, NK cells, CD57, Ki67, TGF-beta, TMABackground
Soft tissue sarcomas (STS) are heterogeneous malignan-
cies originating from the mesenchymal lineage. There
are more than 50 different histological entities and they
comprise less than 1% of adult malignancies [1]. The
STS are among the most aggressive cancer types with a
lethality of 40–50% due to metastasis or local relapse [2].
There are several prognostic factors which determine
tumor progression, and ultimately the patient’s outcome,
including positive resection margins, presence of local
recurrence, histological entity and tumor grade, size, lo-
cation and depth [3-9].* Correspondence: sveinung.sorbye@unn.no
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which permits unrestricted use, distribution, andMany studies have been designed to investigate the
prognostic factors of STS by using immunohistochemical
methods [10], and most of the published data have fo-
cused on the expression of markers for cell kinetics and
regulatory proteins of the cell cycle.
Immunotherapy and vaccines with the capability to acti-
vate the host immune system may have a role as second-
line therapy, and characterization of the in situ cellular
and molecular immunology form the basis for such ther-
apy [11]. Hence, clinical data on the prognostic signifi-
cance of different immunological cells are warranted.
The innate immune system consists mainly of granulo-
cytes, macrophages, natural killer (NK) cells, dendritic
cells (DCs) and their corresponding growth factors and
receptors [12]. They mediate major histocompatibility. This article is published under license to BioMed Central Ltd. This is an Open
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
reproduction in any medium, provided the original work is properly cited.
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immediate limitation and elimination of foreign chal-
lenges to the host, including defense against cancer, but
lack the ability of ‘memory’ when re-exposed to the same
antigen[12,13]. The NK cell has a well-established role in
tumor rejection in a variety of cancers[14-16], and the
mechanism by which these cells discriminate tumor from
normal cells has provided new insights into tumor
immunosurveillance and has suggested new strategies in
the treatment of human cancer [17,18].
Ki67 expression increases with increasing malignancy
grade in many cancer types of different lineages [19-23].
In Ewing’s sarcoma, high Ki67 expression was an inde-
pendent prognostic factor for progression free survival
and overall survival independent of treatment type [24].
We have previously reported the prognostic significance
of the humoral immune system by lymphocyte infiltration
in tumor [25] and peritumoral capsule [26] of STS. We
have also reported the significance of the innate immune
system by the correlation of expression of macrophages
(CD68), their growth factor macrophage colony-stimulating
factor (M-CSF), its receptor colony-stimulating factor-1 re-
ceptor (CSF-1R) and histological grade in STS [27]. It was
important to validate these findings in a different material,
explore the relationship to expression of Ki67, disease-
specific survival (DSS) and include other markers as CD57
and TGF-beta. The purpose of this study was to examine
the prognostic role of the innate immune system in STS by
assessing the expression of CD68, M-CSF, CSF-1R, CD57,
TGF-beta and Ki67.
Methods
Patients and clinical samples
The National Cancer Data Inspection Board and The Re-
gional Committee for Research Ethics approved the
study. The material was collected from our approved
biobank for paraffin embedded material and slides. Data
were analyzed anonymously.
Primary tumor tissue from untreated patients diag-
nosed with STS at the University Hospital of North
Norway (UNN) from 1973 to 2006 and the Hospitals of
Arkhangelsk region, Russia, from 1996 to 2006 was used
in this retrospective study. 496 potentially suitable pa-
tient records were identified from the hospital database,
but only 249 of these were eligible based on complete
medical records and adequate paraffin-embedded tissue
blocks. In 80 of these cases it was also possible to obtain
tissue from the peritumoral capsule for TMA [26]. This
report includes follow-up data for 167 Norwegian and 82
Russian patients until September 2009. The median fol-
low-up was 38 (range 0–392) months.
The histology of all soft tissue sarcoma cases was
reviewed according to modern classification (WHO,
2002) by two dedicated pathologists (AV and SWS). Forthe Russian material, new slides were made from all par-
affin blocks. For the Norwegian material, new slides were
made when necessary. All biopsies were immunostained
with cytokeratin (CK), c-kit (CD117), Actin, smooth
muscle actin (SMA), vimentin (VIM) and CD34. Some
slides were also stained with S100 if necessary to rule
out differential diagnoses. Further molecular methods
were, in general, not considered necessary for differential
diagnostics, but in some cases PCR or FISH were per-
formed. About 10% of the initial diagnoses were revised
due to altered classification and the appearance of new
entities such as GIST. All carcinosarcomas, endometrial
sarcomas, carcinomas and lymphomas were excluded.
Microarray construction
Tissue microarrays (TMAs) were constructed for high-
throughput molecular pathology research[28-30]. The
slides were evaluated by two pathologists (AV and SWS)
using light microscope to identify the tumor and the
peritumoral capsule. The most representative areas of
the tumor and peritumoral capsule were carefully
selected and marked on the hematoxylin and eosin (HE)
slides for the corresponding donor blocks and sampled
for the tissue microarray collector blocks[26]. The TMAs
were assembled using a tissue-arraying instrument (Bee-
cher Instruments).
Studies suggest that punching multiple 0.6 mm cores
from different regions captures the heterogeneity of the
capsule more accurately than single 2 to 4 mm cores
[30]. Hence, we obtained two 0.6-mm cores of tumor
and two cores from peritumoral capsule (four cores from
each patient). These were secured from different repre-
sentative areas of the tissue block and selected to be as
representative as possible. To include all core samples,
12 tissue array blocks were constructed. Multiple 4-μm
sections were cut with a Micron microtome (HM355S)
and specific antibodies were stained for immunohisto-
chemistry (IHC).
Immunohistochemistry (IHC)
Sections were deparaffinized with xylene and rehydrated
with ethanol. Antigen retrieval was performed by placing
the specimens in 0.01 M citrate buffer at pH 6.0 and ex-
posing them to two repeated microwave heatings of
10 min at 450 W. The slides were then transferred to the
Ventana Benchmark, XT automated slide stainer (Ven-
tana Medical System, Illkirch, France). Tissue sections
were incubated with primary mouse monoclonal anti-
bodies recognizing Ki67, CD68 and CD57 (Ventana
Medical System), as well as rabbit polyclonal M-CSF,
CSF-1R (clone H-300; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and TGF-beta (clone sc-146; Santa
Cruz). The dilution was 1:5 for M-CSF, 1:25 for CSF-1R
and 1:50 for TGF-beta. All Ventana antibodies were
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were 16 min for Ki67, CD57 and CD68, and 28 min for
TGF-beta, M-CSF and CSF-1R. As secondary antibodies,
biotinylated goat antimouse IgG and mouse antirabbit
IgM, both 200 lg ml, were used. The Dako EnVision +
System-Horseradish Peroxidase [diaminobenzidine
(DAB)] kit (Dako, Glostrup, Denmark) was used to block
endogenous peroxidase. This was followed by application
of liquid diaminobenzidine as substrate-chromogen,
yielding a brown reaction product at the site of the target
antigen (iView DABW procedure). Finally, slides were
counterstained with hematoxylin to visualize the nuclei.
For each antibody, including controls, all TMA staining
were performed in a single experiment. As negative
staining controls, the primary antibodies were replaced
with the primary antibody diluents. In the TMA we also
used cores from carcinomas and normal tissue as posi-
tive and negative controls.Scoring of IHC
The ARIOL imaging system (Genetix, San Jose, CA) was
used to scan the slides for antibody staining of the TMAs
[26]. The number of CD57 positive cells (including NK
cells) and CD68 positive cells (including macrophages) in
tumors were scored as 0 (no cells), 1 (1–5 cells), 2 (6–19) or
3 (20+ cells) per 0.6 mm core. Examples are shown in
Figure 1. Regarding M-CSF, CSF-1R, Ki67 and TGF-beta,M-CSF neg M
CD68 neg C
Figure 1 IHC microscopic pictures of TMA of soft tissue sarcoma repr
expression; (B) CD68 high expression; (C) M-CSF low expression; (D) M-CSFexpression was scored as: 0, negative; 1, weak; 2, intermedi-
ate; and 3, strong. The mean score from the duplicate cores
from tumor or capsule, respectively, was used. Marker ex-
pression was dichotomised (low vs. high), and high expres-
sion defined as mean score≥0.30 for CD68, ≥ 0.75 for
TGF-beta, ≥ 2.00 for Ki67 and≥0.01 for CD57, M-CSF and
CSF-1R. All samples were anonymized and independently
scored by two pathologists (AV and SWS). When disagree-
ment, the slides were re-examined and consensus was
reached by the observers. When assessing a variable for a
given score, the scores of the other variables and the out-
come were hidden from the observers.Statistical methods
All statistical analyses were done using the statistical
package SPSS (Chicago, IL), version 18. The immunohis-
tochemistry scores from each observer were compared
for interobserver reliability by use of a two-way random
effect model with absolute agreement definition. The
intraclass correlation coefficient (reliability coefficient)
was obtained from these results.
The Chi-square test and Fishers Exact test were used
to examine the association between molecular marker
expression and various clinicopathological variables. Uni-
variate analyses were performed using the Kaplan-Meier
method, and statistical significance between survival
curves was assessed by the log rank test. Disease-specific-CSF pos
D68 pos
esenting different expression of CD68 and M-CSF. (A) CD68 low
high expression. Original magnification X 100 and 400.
Table 1 Prognostic clinicopathological variables as predictors for disease-specific survival soft tissue sarcomas
(univariate analysis, log rank test), N = 249







≤ 20 years 20 8 15 40 0.126
21-60 years 113 45 68 52
> 60 years 116 47 30 40
Gender
Male 110 44 41 46 0.390
Female 139 56 45 45
Nationality
Norwegian 167 67 63 51 0.011
Russian 82 33 22 34
Histology
Undifferentiated pleomorphic sarcoma 68 27 29 40 0.102
Leiomyosarcoma 67 27 45 46
Liposarcoma 34 14 NR 67
MF/MFT 20 8 43 50
Angiosarcoma 13 5 10 31
Rhabdomyosarcoma 16 6 17 38
MPNST 11 4 49 45
Synovial sarcoma 16 6 31 29
Other STS 4 2 NR 75
Tumor localization
Extremities 89 36 100 53 0.348
Trunk 47 29 32 44
Retroperitoneum 37 25 25 38
Head/Neck 18 7 15 41
Visceral 58 23 30 42
Tumor size
< 5 cm 74 30 127 57 0.027
5-10 cm 91 37 44 45
> 10 cm 81 32 28 37
Missing 3 1
Malignancy grade FNCLCC
1 61 25 NR 74 <0.001
2 98 39 41 45
3 90 36 16 26
Tumor depth
Superficial 17 7 NR 93 <0.001
Deep 232 93 36 42
Metastasis at time of diagnosis
No 206 83 76 53 <0.001
Yes 43 17 10 10
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Table 1 Prognostic clinicopathological variables as predictors for disease-specific survival soft tissue sarcomas
(univariate analysis, log rank test), N = 249 (Continued)
Surgery
Yes 228 92 59 50 <0.001
No 21 8 5 0
Surgical margins
Wide 108 43 NR 62 <0.001
Non-wide 141 57 19 33
Chemotherapy
No 191 77 52 47 0.424
Yes 58 23 29 40
Radiotherapy
No 176 71 48 46 0.590
Yes 73 29 38 43
Abbreviations: MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; STS, soft tissue sarcomas; NR, not
reached; NOS, non specified.
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firmed STS diagnosis.
The multivariate analysis was carried out using the
Cox proportional hazards model to assess the independ-
ent impact of each pre-treatment variable on survival in
the presence of other variables. Only significant variables
from the univariate analyses were entered into the Cox
regression analysis. Probability for stepwise entry and re-
moval was set at 0.05 and 0.10, respectively. The signifi-
cance level used was p< 0.05.Results
Clinicopathological variables
Demographic, clinical, and histopathological variables
are shown in Table 1. Patient age range was 0–91 years
(mean 55 years), and 44% of the patients were males.
The non-GIST STS comprised 68 undifferentiated pleo-
morphic sarcoma, 67 leiomyosarcoma, 34 liposarcoma,
20 malignant fibroblastic/myofibroblastic tumors, 16
rhabdomyosarcoma, 16 synovial sarcoma, 13 angiosar-
coma, 11 malignant peripheral nerve sheath tumors
(MPNST) and 4 other STS. There were 61 low grade
STS (24%) and 188 high grade (FNCLCC grade 2 and 3)
STS (76%).
The treatment option of choice was surgery (n = 228),
seven patients received chemotherapy and/or radiother-
apy only, and 14 patients received no therapy. A total of
120 patients received surgery only, 55 surgery and radio-
therapy; 40 surgery and chemotherapy and 13 surgery,
radiotherapy and chemotherapy. Two patients received
chemotherapy only, three both chemotherapy and radio-
therapy, and two radiotherapy only. The 5-year survival
with non-wide resection margins was 33% and with wide
resection margins 62%.Inter-observer variability
There was good reproducibility between the two investi-
gating pathologists. The scoring agreement was tested
for M-CSF and CD68 expression in tumor. The IHC
scores from each observer were compared using a two-
way random effect model with absolute agreement defin-
ition. The intraclass correlation coefficients (reliability
coefficients, r) obtained from these results were 0.85 for
M-CSF (P< 0.001) and 0.90 for CD68 (P< 0.001).Univariate analyses
Nationality, tumor size, malignancy grade, tumor depth,
metastasis at time of diagnosis, surgery and surgical mar-
gins were all significant indicators for disease-specific
survival (DSS) in univariate analyses (Table 1).
Besides, increased expression of M-CSF (P=0.034), Ki67
(P< 0.001) and TGF-beta (p= 0.003) in tumor correlated
significantly with a shorter DSS, (Table 2 and Figure 2).
Co-expression of M-CSF and TGF-beta (p= 0.004) also
correlated with shorter DSS. No such relationship was
observed for CD57, CD68, and CSR-1R.
A shorter DSS with increased expression of M-CSF
was seen in females (P = 0.025), Norwegian patients
(P = 0.015) and in patients with tumors larger than 5 cm
(P = 0.018, data not shown).
Increased expression of Ki67 in the peritumoral cap-
sule correlated with a shorter DSS (N= 80, P< 0.001).
Increased expression of CD68 in the peritumoral capsule
tended to correlate with a shorter DSS, though not sta-
tistically significant (N= 80, P = 0.057), Table 3. No prog-
nostic impact was observed for CD57, M-CSF, CSR-1R,
TGF-beta or co-expression of M-CSF and TGF-beta.
There was a correlation of expression of Ki67 in tumor
















Low expression, n = 31
High expression, n = 139
Medium expression, n = 63
P = 0.001
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High expression, n = 169
P = 0.034
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P = 0.003
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Low/high expression, n = 12
High/low expression, n = 47
High/high expression, n = 101
P = 0.004
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Figure 2 Disease-specific survival curves for high and low expression of CD68, Ki67, M-CSF, TGF-beta and co-expression M-CSF and
TGF-beta in tumor in patients with STS (N= 249).
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peritumoral capsule (N= 80, P = 0.395) and metastasis at
the time of the diagnosis (data not shown).
In co-variation analyses between malignancy grade and
expression of the different markers in tumor, Ki67, CD68,
M-CSF and TGF-beta showed statistical significance (data
not shown). Increased expression of CD68 in tumorcorrelated with malignancy grade (P=0.016) and expres-
sion of Ki67 (P< 0.001). Increased expression of M-CSF in
tumor correlated with malignancy grade (P=0.010) and
expression of Ki67 (P= 0.002). Increased expression of
TGF-beta in tumor correlated with malignancy grade
(P= 0.029) and expression of Ki67 (P= 0.005), table 4 and
5. There was a co-variation between expression of M-CSF
Table 2 Expression of markers in tumor and their
prediction for disease-specific survival in patients with














Low 93 37 54 49 0.617
High 135 54 49 48
Missing 21 8
CD 68
Low 57 23 91 52 0.270
High 172 69 45 47
Missing 20 8
M-CSF
Low 56 22 NR 59 0.034
High 169 68 38 44
Missing 24 10
CSF-1R
Low 38 15 41 44 0.832
High 191 77 38 46
Missing 20 8
Ki67
Low 31 12 NR 63 <0.001
Medium 63 25 NR 59
High 139 56 24 37
Missing 16 6
TGF-beta
Low 117 47 99 53 0.003
High 122 49 29 37
Missing 10 4
M-CSF and TGF-beta
Low 119 48 91 53 0.004
High 101 41 29 38
Missing 29 12
Abbreviations: NR, not reached.
Table 3 Expression of markers in peritumoral capsule and
their prediction for disease-specific survival in patients
with soft tissue sarcomas (univariate analysis; log-rank













Low 50 63 38 47 0.797
High 29 36 123 55
Missing 1 1
CD 68
Low 34 43 NR 61 0.057
High 45 56 31 43
Missing 1 1
M-CSF
Low 36 45 75 54 0.608
High 39 49 36 46
Missing 5 6
CSF-1R
Low 36 45 52 49 0.587
High 37 46 57 47
Missing 7 9
Ki67
Low 32 40 NR 74 <0.001
High 37 46 29 35
Missing 11 14
TGF-beta
Low 43 54 52 50 0.906
High 28 35 31 50
Missing 9 11
M-CSF and TGF-beta
Low 24 30 80 57 0.626
High 42 53 31 45
Missing 14 18
Abbreviations: NR, not reached.
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crosstabulation the expected count in the low M-CSF, high
TGF-beta group was 26.7 patients (data not shown), but
the observed count was 12 patients (Figure 2).
Multivariate analyses
Significant demographic, clinicopathological, and expres-
sion variables from the univariate analyses were entered
into the multivariate Cox regression analysis. In the
multivariate analysis, the co-expression of M-CSF and
TGF-beta in the tumor was an independent prognosticfactor for DSS. Other independent negative prognostic
variables were malignancy grade (P< 0.001), metastasis
at time of diagnosis (P< 0.001) and non-wide resection
margins (P = 0.001, Table 6).
In patients with tissue from peritumoral capsule, inde-
pendent negative prognostic variables were non-wide re-
section margins (P = 0.031) and high expression of Ki67
(P = 0.019, Table 6)
Discussion
In this study we evaluated whether there is an associ-
ation between the expression of CD57, CD68, M-CSF,
CSF-1R, Ki67 and TGF-beta in tumors or peritumoral
Table 4 Results of expression of CD68 and M-CSF in
tumor versus malignancy grade in patients with soft
tissue sarcomas, N =249
Expression Malignancy grade (%)
Grade 1 Grade 2 Grade 3 Total
CD68, Low 23 (40) 16 (28) 18 (32) 57 (100)
CD68, High 37 (22) 73 (42) 62 (36) 172 (100)
Total 60 (26) 89 (39) 80 (35) 229 (100)
Missing 20 Chi-Square 8.319
P-value 0.016
Grade 1 Grade 2 Grade 3 Total
M-CSF, Low 23 (41) 18 (32) 15 (27) 56 (100)
M-CSF, High 35 (21) 67 (40) 67 (40) 169 (100)
Total 58 (26) 85 (38) 82 (37) 225 (100)
Missing 24 Chi-Square 9.300
P-value 0.010
Grade 1 Grade 2 Grade 3 Total
TGF-beta, Low 15 (13) 66 (56) 36 (31) 117 (100)
TGF-beta, High 6 (5) 71 (58) 45 (37) 122 (100)
Total 21 (9) 137 (57) 81 (34) 239 (100)
Missing 10 Chi-Square 7.091
P-value 0.029
Table 5 Results of expression of CD68 and M-CSF in
tumor versus expression of Ki67 in patients with soft
tissue sarcomas, N =249
Expression Ki67 (%)
Low Medium High Total
CD68, Low 15 (27) 19 (35) 21 (38) 55 (100)
CD68, High 15 (9) 42 (25) 110 (66) 167 (100)
Total 30 (14) 61 (28) 131 (59) 222 (100)
Missing 27 Chi-Square 16.947
P-value <0.001
Low Medium High Total
M-CSF, Low 14 (26) 16 (30) 23 (43) 53 (100)
M-CSF, High 15 (9) 41 (25) 108 (66) 164 (100)
Total 29 (13) 57 (26) 131 (60) 217 (100)
Missing 32 Chi-Square 12.695
P-value 0.002
Low Medium High Total
TGF-beta, Low 21 (18) 34 (30) 59 (52) 114 (100)
TGF-beta, High 7 (6) 28 (25) 79 (69) 114 (100)
Total 28 (12) 62 (27) 138 (31) 228 (100)
Missing 21 Chi-Square 10.749
P-value 0.005
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Increased co-expression of M-CSF and TGF-beta in the
tumor and increased expression of Ki67 in the peritu-
moral capsule were independent negative prognostic fac-
tors for DSS in patients with STS. High expression of M-
CSF in tumor was correlated with high malignancy
grade, increased Ki67 and short DSS. To our knowledge,
this is the first report on co-expression of M-CSF and
TGF-beta in STS and the first evidence of its possible
clinical relevance in STS patients.
STS have varying biological characteristics regardless
of histological entities. Its prognosis is poor, but also dif-
ficult to predict. This aggressive behavior reflects, at least
in part, the capacity of the tumor to evade host immune
surveillance. Evasion strategies can protect cancer cells
from immune responses by a variety of mechanisms in-
cluding self-tolerance, sequestration of tissue from sur-
veillance, antigen shedding, lymphocyte killing, secretion
of immunosuppressive cytokines, lack of MHC II expres-
sion, lack of co-stimulatory molecules and local secretion
of prostaglandins.
CD57 positive cells have been implicated in the resist-
ance against malignant and virally-infected cells. Pres-
ence of these cells was observed to be an independent
prognostic marker for a better DSS in squamous cell car-
cinoma [31] and adenocarcinoma [32] of the lung, as
well as in other cancers such as colonic and gastric car-
cinomas [14,15]. In NSCLS, high density of stromalCD57 positive cells was an independent, positive prog-
nostic factor for DSS, whereas high density of CD57
positive cells within neoplastic cell areas was not [33]. In
our material there was no such correlation in tumor or
peritumoral capsule. The location of infiltrating lympho-
cytes may be important. There are major differences be-
tween 1) inflammatory cells within cancer cell nests in
carcinomas (epithelial CD57 positive cells); 2) inflamma-
tory cells present in the stroma of epithelial tumors
(stromal CD57 positive cells), 3) inflammatory cells
present along the invasive margins (peritumoral CD57
positive cells); and, 4) inflammatory cells in the peritu-
moral capsule of stromal tumors such as STS.
In addition to NK-cells, expression of CD57 is also found
on T-lineage lymphocytes, where it is currently considered
a marker-replicative senescence (“clonal exhaustion”), i.e., a
high susceptibility to activation-induced cell death and the
inability to undergo new cell-division cycles despite pre-
served ability to secrete cytokines upon encounter with
their cognate antigen [34]. Even on NK cells it does not
constitute a one-marker-labels-all solution: CD57 defines a
functionally distinct population of mature NK cells in the
human CD56dim CD16+ NK-cell subset [35].
Studies have demonstrated a close association between
M-CSF and tumor progression in lung cancer cell lines
[36]. In a NSCLC cohort studied by Kaminska et al. [37],
high pretreatment serum levels of M-CSF were an inde-
pendent predictor of poor survival in these patients.
Table 6 Results of Cox regression analysis summarizing significant independent prognostic factors in patients with soft
tissue sarcomas
Tumor, N=249 Capsule, N=80
Factor Hazard
Ratio





Russian 0.948 0.603-1.490 0.816 0.588 0.263-1.312 0.194
Tumor size
< 5 cm 1.000 0.540* 1.000 0.342*
5-10 cm 1.103 0.687-1.770 0.685 0.888 0.376-2.099
> 10 cm 1.310 0.797-2.153 0.287 1.671 0.660-4.233
Malignancy grade
FNCLCC
1 1.000 0.001* 1.000 0.051*
2 1.997 1.129-3.531 0.017 1.402 0.383-5.137 0.610
3 2.874 1.617-5.107 <0.001 2.954 0.837-10.432 0.092
Metastasis at time of
diagnosis
No 1.000 1.000
Yes 2.842 1.855-4.354 <0.001 2.101 0.901-4.898 0.086
Resection margins
Wide 1.000 1.000
Non-wide 2.523 1.706-3.730 <0.001 2.245 1.077-4-680 0.031
Ki67
Low 1.000 0.432* 1.000
Medium 1.059 0.528-2.163 0.876 - - -
High 1.365 0.710-2.625 0.351 2.553 1.167-5.584 0.019
M-CSF
Low 1.000 NIA
High 0.815 0.463-1.435 0.478
TGF-beta
Low 1.000 NIA
High 0.682 0.247-1.881 0.460
M-CSF and TGF-beta
Low 1.000 NIA
High 1.532 1.062-2.208 0.022
* Overall significance as a prognostic factor. NIA =Not included in analysis.
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between expression of M-CSF in NSCLC and DSS. CSF-
1 protected osteoclasts from suppressive effects of trans-
forming growth factor beta (TGF-beta) in a mouse mam-
mary tumor cell line [38]. Kirma et al. studied M-CSF
and TGF-beta in cervical cancer and found that CSF-1R
(c-fms proto-oncogene product) activation may play a
role in cervical carcinogenesis [39]. Richardsen et al. [27]
showed that high M-CSF expression was correlated with
a high malignancy grade in STS. In our study, high M-
CSF expression in tumor correlated with a highmalignancy grade, increased Ki67 and DSS in univariate
analyses. But the expression of M-CSF in peritumoral
capsule showed no correlation with DSS.
TGF-beta is a multifunctional cytokine known to induce
G1 arrest in order to end proliferation, induce differenti-
ation, or promote apoptosis in normal cells, thus being a
natural tumor-suppressive agent. Though in tumorigenesis
this mediator initiates EMT through activation of Smad and
non-Smad signalling pathways[40]. Such pro-neoplastic ac-
tion becomes possible through either blockade of the TGF-
beta pathway with receptor-inactivating mutations, or
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pathway[41]. High TGF-beta expression was an independ-
ent negative prognostic factor for disease specific survival in
STS[42]. In the multivariate analysis, co-expression of M-
CSF and TGF-beta were an even stronger negative prognos-
tic factor in this study. We found a co-variation of expres-
sion of M-CSF and TGF-beta in tumor. TFG-beta might
regulate the expression of M-CSF. Grayfer et al. reported
on the regulation of pro-inflammatory functions of goldfish
macrophages and induction of gene expression by recom-
binant goldfish CSF-1 (rgCSF-1). At 72 h post treatment
rgCSF-1 increased the expression of TGF-beta [43]. The
combined expression of immunostimulatory granulocyte
macrophage colony stimulating factor (GM-CSF) and anti-
tumor suppressor TGF-β2 antisense (AS) transgenes can
break tolerance and stimulate immune responses to cancer-
associated antigens which make it possible to design bifunc-
tional therapeutic anti-cancer vaccines[44].
Increased expression of Ki67 and M-CSF in tumor are
negative prognostic indicators for patients with STS, but
this is not independent of malignancy grade. In the univari-
ate analysis presented TGF-beta seems to be the dominat-
ing factor, while low or high M-CSF expression in
combination with low TGF-beta expression does not seem
to influence prognosis significantly. Both expression of
TGF-beta and M-CSF have co-variation with malignancy
grade and expression of Ki67. In the multivariate analysis
the co-expression of M-CSF and TGF-beta was a stronger
prognosticator for DSS than each of the markers alone. Ex-
pression of Ki67 in tumor was not an independent prognos-
ticator. As mitotic activity is one of the criteria determining
the malignancy grade, expression of Ki67 is closely corre-
lated to mitotic activity, hence also malignancy grade [45].
Archad et al. found that malignancy grade is a more import-
ant prognostic factor in glial neoplasms than Ki67 [19]. So
Ki67 may not provide additional information if the tumor
malignancy grade is classified correctly. The tumor stroma
is important for cancer progression [46]. There is no evalu-
ation of tumor stroma in the grading systems of STS. But
Ki67 expression in the peritumoral capsule may have prog-
nostic impact in addition to malignancy grading of the
tumor. Further research is needed to determine whether an
increased expression of Ki67 may be the result of on
increased migration of fast-proliferating cells in the peritu-
moral capsule or an enhanced proliferation effect of tumor-
released cytokines on the stromal cells.Conclusion
In summary, increased co-expression of M-CSF and TGF-
beta in tumor and increased Ki67 expression in the peritu-
moral capsule of STS patients were independent negative
prognostic factors for DSS. This data may provide add-
itional information to guide therapy after surgical resection.Acknowledgements
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